share_log

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT：其他
美股sec公告 ·  06/17 18:15
牛牛AI助理已提取核心訊息
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of June 14, 2024, at 4:30 P.M. This form is typically used by non-U.S. companies for registering securities for an initial public offering (IPO) in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals has met all the necessary regulatory requirements to proceed with its IPO.
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of June 14, 2024, at 4:30 P.M. This form is typically used by non-U.S. companies for registering securities for an initial public offering (IPO) in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals has met all the necessary regulatory requirements to proceed with its IPO.
美國證券交易委員會（SEC）已宣佈Biodexa Pharmaceuticals Plc的F-1表格自2024年6月14日下午4:30生效。此表格通常用於非美國公司在美國進行首次公開發行股票（IPO）的證券註冊。表格的有效性表明Biodexa Pharmaceuticals已滿足所有必要的監管要求，可以繼續進行其IPO。
美國證券交易委員會（SEC）已宣佈Biodexa Pharmaceuticals Plc的F-1表格自2024年6月14日下午4:30生效。此表格通常用於非美國公司在美國進行首次公開發行股票（IPO）的證券註冊。表格的有效性表明Biodexa Pharmaceuticals已滿足所有必要的監管要求，可以繼續進行其IPO。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。